Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.

Publication ,  Journal Article
Qu, W; Wang, Z; Engelberg-Cook, E; Yan, D; Siddik, AB; Bu, G; Allickson, JG; Kubrova, E; Caplan, AI; Hare, JM; Ricordi, C; Pepine, CJ ...
Published in: Stem Cells Transl Med
July 20, 2022

MSC (a.k.a. mesenchymal stem cell or medicinal signaling cell) cell therapies show promise in decreasing mortality in acute respiratory distress syndrome (ARDS) and suggest benefits in treatment of COVID-19-related ARDS. We performed a meta-analysis of published trials assessing the efficacy and adverse events (AE) rates of MSC cell therapy in individuals hospitalized for COVID-19. Systematic searches were performed in multiple databases through November 3, 2021. Reports in all languages, including randomized clinical trials (RCTs), non-randomized interventional trials, and uncontrolled trials, were included. Random effects model was used to pool outcomes from RCTs and non-randomized interventional trials. Outcome measures included all-cause mortality, serious adverse events (SAEs), AEs, pulmonary function, laboratory, and imaging findings. A total of 736 patients were identified from 34 studies, which included 5 RCTs (n = 235), 7 non-randomized interventional trials (n = 370), and 22 uncontrolled comparative trials (n = 131). Patients aged on average 59.4 years and 32.2% were women. When compared with the control group, MSC cell therapy was associated with a reduction in all-cause mortality (RR = 0.54, 95% CI: 0.35-0.85, I  2 = 0.0%), reduction in SAEs (IRR = 0.36, 95% CI: 0.14-0.90, I  2 = 0.0%) and no significant difference in AE rate. A sub-group with pulmonary function studies suggested improvement in patients receiving MSC. These findings support the potential for MSC cell therapy to decrease all-cause mortality, reduce SAEs, and improve pulmonary function compared with conventional care. Large-scale double-blinded, well-powered RCTs should be conducted to further explore these results.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Stem Cells Transl Med

DOI

EISSN

2157-6580

Publication Date

July 20, 2022

Volume

11

Issue

7

Start / End Page

688 / 703

Location

England

Related Subject Headings

  • Respiratory Distress Syndrome
  • Male
  • Humans
  • Female
  • Cell- and Tissue-Based Therapy
  • COVID-19
  • Aged
  • 4003 Biomedical engineering
  • 3206 Medical biotechnology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Qu, W., Wang, Z., Engelberg-Cook, E., Yan, D., Siddik, A. B., Bu, G., … Sanfilippo, F. P. (2022). Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Stem Cells Transl Med, 11(7), 688–703. https://doi.org/10.1093/stcltm/szac032
Qu, Wenchun, Zhen Wang, Erica Engelberg-Cook, Dan Yan, Abu Bakar Siddik, Guojun Bu, Julie G. Allickson, et al. “Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.Stem Cells Transl Med 11, no. 7 (July 20, 2022): 688–703. https://doi.org/10.1093/stcltm/szac032.
Qu W, Wang Z, Engelberg-Cook E, Yan D, Siddik AB, Bu G, et al. Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Stem Cells Transl Med. 2022 Jul 20;11(7):688–703.
Qu, Wenchun, et al. “Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.Stem Cells Transl Med, vol. 11, no. 7, July 2022, pp. 688–703. Pubmed, doi:10.1093/stcltm/szac032.
Qu W, Wang Z, Engelberg-Cook E, Yan D, Siddik AB, Bu G, Allickson JG, Kubrova E, Caplan AI, Hare JM, Ricordi C, Pepine CJ, Kurtzberg J, Pascual JM, Mallea JM, Rodriguez RL, Nayfeh T, Saadi S, Durvasula RV, Richards EM, March K, Sanfilippo FP. Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Stem Cells Transl Med. 2022 Jul 20;11(7):688–703.

Published In

Stem Cells Transl Med

DOI

EISSN

2157-6580

Publication Date

July 20, 2022

Volume

11

Issue

7

Start / End Page

688 / 703

Location

England

Related Subject Headings

  • Respiratory Distress Syndrome
  • Male
  • Humans
  • Female
  • Cell- and Tissue-Based Therapy
  • COVID-19
  • Aged
  • 4003 Biomedical engineering
  • 3206 Medical biotechnology
  • 1103 Clinical Sciences